Home pageAPNHY • OTCMKTS
add
Aspen Pharmacare
Chiusura precedente
6,79Â $
Intervallo giornaliero
6,77Â $ - 6,77Â $
Intervallo annuale
5,76Â $ - 13,69Â $
Cap di mercato
53,55Â Mld ZAR
Volume medio
1988,00
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
(ZAR) | dic 2024info | Variazione Y/Y |
---|---|---|
Entrate | 10,98Â Mld | 3,87% |
Spese di gestione | 3,28Â Mld | 12,84% |
Utile netto | 1,19Â Mld | 3,20% |
Margine di profitto netto | 10,87 | -0,73% |
Utili per azione | — | — |
EBITDA | 2,47Â Mld | 11,05% |
Aliquota fiscale effettiva | 25,02% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(ZAR) | dic 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 6,80Â Mld | -41,33% |
Totale attivo | 136,60Â Mld | -1,93% |
Totale passivo | 51,51Â Mld | -4,06% |
Patrimonio netto totale | 85,09 Mld | — |
Azioni in circolazione | 444,10 Mln | — |
Prezzo/valore contabile | 0,04 | — |
Redditività dell'attivo | 3,56% | — |
Rendimento sul capitale | 4,04% | — |
Flusso di cassa
Flusso di cassa netto
(ZAR) | dic 2024info | Variazione Y/Y |
---|---|---|
Utile netto | 1,19Â Mld | 3,20% |
Liquidità di esercizio | 902,50 Mln | -26,57% |
Contanti da investimenti | -1,40Â Mld | 54,76% |
Contanti da finanziamenti | 479,50Â Mln | -75,45% |
Flusso di cassa netto | -208,00Â Mln | -427,56% |
Flusso di cassa libero | 155,00Â Mln | 185,99% |
Informazioni
Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union. Wikipedia
CEO
Fondazione
1850
Sito web
Dipendenti
9.109